Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Amarin (AMRN)

Add to Watchlists
Create an Alert
1.615 -0.01  -0.92% NASDAQ Apr 23, 3:07PM BATS Real time Currency in USD
View Full Chart
AMRN Price Chart
View All Events

AMRN Events

Date Type Description
Feb 27 Misc Amarin Corporation PLC Q4 2013 Earning Conference Call
Feb 27 Earnings Amarin Corporation PLC Q4 2013 Earning Result. Estimate: -0.21.
Nov 07 Misc Amarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013
Nov 07 Earnings Amarin to Report Third Quarter 2013 Results. Estimate: -0.34.
Oct 16 Misc Amarin to Host Conference Call on October 16, 2013 to Discuss Results of Fda Advisory Committee Meeting on Anchor Supplemental New Drug Application (Snda) for Vascepa(r)
Aug 08 Misc Amarin to Report Second Quarter 2013 Results and Host Conference Call on August 8, 2013
Aug 08 Earnings Amarin Announces Second Quarter 2013 Results. Estimate: -0.42.
Jul 09 Misc AGM Event for Amarin Corp
May 09 Misc Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
May 09 Earnings Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013. Estimate: -0.32.
View All Performance Charts

AMRN Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Amarin is down 76.42% over the last year vs S&P 500 Total Return up 22.65%, Actelion up 71.93%, and Alexza Pharmaceuticals down 1.60%.

Get Quote for

Portfolio Strategies Featuring AMRN

Did Amarin make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

AMRN Profile

  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Headquarters Country: Ireland
  • Headquarters State/Province: N/A
  • Incorporation Country: United Kingdom
  • Incorporation State/Province: N/A
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). The firm has completed two pivotal Phase 3 studies of AMR101 which include Marine and Anchor under the Special Protocol Assessment agreements with the U.S. Food and Drug Administration. The company was founded on March 1, 1989 and is headquartered in Dublin, Ireland.

Recent Quotes

Symbol Price Chg Chg % Market Cap
AMRN 1.615 -0.01 -0.92% 278.49M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.